Phaseline

Companies › Bisirna Therapeutics Pte.

Bisirna Therapeutics Pte.: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Hematology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VSA012
Complement system inhibitor
–Phase 1Paroxysmal Nocturnal Hemoglobinuria (PNH)Feb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06848296VSA012Phase 1Paroxysmal Nocturnal Hemoglobinuria (PNH)HematologyFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.